Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission

Overview of attention for article published in Frontiers in immunology, January 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 54,263 followers.

RT @CARTTherapy: CAR T Cell Therapy Improve the Prognosis of Pediatric ALL With Persistent/Recurrent MRD in First Complete Remission https:…

RT @CARTTherapy: CAR T Cell Therapy Improve the Prognosis of Pediatric ALL With Persistent/Recurrent MRD in First Complete Remission https:…

RT @CARTTherapy: CAR T Cell Therapy Improve the Prognosis of Pediatric ALL With Persistent/Recurrent MRD in First Complete Remission https:…

RT @CARTTherapy: CAR T Cell Therapy Improve the Prognosis of Pediatric ALL With Persistent/Recurrent MRD in First Complete Remission https:…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.